Acute Agitation And Aggression Treatment Market Outlook and Analysis Through 2024-2033: Evaluating Growth Opportunities

The acute agitation & aggression treatment market size has grown strongly in recent years. It will grow from $5.4 billion in 2023 to $5.72 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to advances in pharmacology, rise in clinical research, regulatory approvals, rise in prevalence of acute agitation and aggression cases, increased awareness regarding mental health .

The acute agitation & aggression treatment market size is expected to see strong growth in the next few years. It will grow to $7.23 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to growing aging population, growing healthcare infrastructure, rising pharmaceutical industry investment, rise in home-base care, rise in disposable income. Major trends in the forecast period include non-pharmacological interventions, precision medicine, ai and predictive analytics, community-based support, industry collaboration.

Market Overview -
Acute agitation and aggression treatment refers to the medical and therapeutic interventions to manage and reduce the sudden onset of restlessness, irritability, and hostility in patients. These agitated and aggressive behaviors can be symptoms of various underlying conditions, including psychiatric disorders, neurological disorders, or substance use or withdrawal effects.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=13078&type=smp

Rising Dementia Incidence Fuels Growth In Acute Agitation And Aggression Treatment Market
The increase in the incidence of dementia is expected to propel the growth of the acute agitation and aggression treatment market going forward. Dementia refers to conditions characterized by impaired memory, cognition, and the capability to manage everyday tasks. A symptom often observed in dementia patients is agitation, manifested through behaviors such as restlessness, repetitive actions, or frequent hand movements. Acute agitation and aggression treatment play a key role in dementia. It reduces the risk of harmful symptoms, improves the patient's quality of life, and manages the underlying cause of the agitation. For instance, in February 2023, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2022, it was projected that about 401,300 Australians have dementia, and this figure is anticipated to be doubled to reach 849,300 in 2058. Therefore, the increase in the incidence of dementia is driving the growth of the acute agitation and aggression treatment market.

Competitive Landscape -
Major companies operating in the acute agitation and aggression treatment market market include Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd, AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd, AstraZeneca PLC, Ono Pharmaceutical Co Ltd, Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc, Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc

Innovative Sublingual Film Igalmi (Dexmedetomidine) Revolutionizes Acute Agitation Treatment Market
Major companies operating in the acute agitation and aggression treatment market are developing innovative products and getting approved, such as IGALMI (dexmedetomidine), to provide a new treatment option for patients with agitation associated with schizophrenia or bipolar disorder. IGALMI (dexmedetomidine) is a sublingual film used to treat acute agitation associated with schizophrenia or bipolar I or II disorder in adults. For instance, in April 2022, BioXcel Therapeutics Inc., a US-based biopharmaceutical company, received IGALMI (dexmedetomidine) approval from the Food and Drug Administration. It is a quick-acting drug that starts working in a matter of minutes. It is also a short-acting medication, with effects lasting for about 2 hours. It can significantly improve existing therapies for a severe or life-threatening condition.

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/acute-agitation-and-aggression-treatment-global-market-report

Key Segments -

The acute agitation and aggression treatment market market covered in this report is segmented -
1) By Treatment Approach: Behavioral Approaches, Environmental Interventions, Pharmacologic Approaches
2) By Drug Class: Anti-Psychotics, Benzodiazepines, Other Drug Classes
3) By Route of Administration: Oral, Intramuscular, Other Routes of Administrations
4) By Indication: Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-Induced Agitation And Aggression, Alcohol Withdrawal, Other Indications
5) By End User: Hospitals And Ambulatory Surgical Centers, Psychiatric Care Facilities, Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

"Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

"Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps"

This release was published on openPR.